Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 509

1.

Surgery in recurrent ovarian cancer.

Sehouli J, Grabowski JP.

Cancer. 2019 Dec 15;125 Suppl 24:4598-4601. doi: 10.1002/cncr.32511. Review.

PMID:
31967681
2.

The role of acculturation in migrants' use of gynecologic emergency departments.

Schwachenwalde S, Sauzet O, Razum O, Sehouli J, David M.

Int J Gynaecol Obstet. 2020 Jan 17. doi: 10.1002/ijgo.13099. [Epub ahead of print]

PMID:
31953838
3.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators.

N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.

PMID:
31851799
4.

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.

Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, Hamilton A, Fiorica J, Moore KN, Teneriello M, Golden L, Zhang W, Pitou C, Bell R, Campbell R, Farrington DL, Bell-McGuinn K, Wenham RM.

Gynecol Oncol. 2020 Jan;156(1):23-31. doi: 10.1016/j.ygyno.2019.11.006. Epub 2019 Nov 29.

PMID:
31791552
5.

Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer.

Muallem MZ, Sehouli J, Richter R, Babayeva A, Gasimli K, Parashkevova A.

Int J Gynecol Cancer. 2020 Jan;30(1):62-66. doi: 10.1136/ijgc-2019-000778. Epub 2019 Nov 19.

PMID:
31744887
6.

EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.

Naskou J, Beiter Y, van Rensburg R, Honisch E, Rudelius M, Schlensog M, Gottstein J, Walter L, Braicu EI, Sehouli J, Darb-Esfahani S, Staebler A, Hartkopf AD, Brucker S, Wallwiener D, Beyer I, Niederacher D, Fehm T, Templin MF, Neubauer H.

Mol Cancer Res. 2019 Nov 8. doi: 10.1158/1541-7786.MCR-19-0141. [Epub ahead of print]

PMID:
31704732
7.

Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer.

Mao X, Dong B, Gao M, Ruan G, Huang M, Braicu EI, Sehouli J, Sun P.

Onco Targets Ther. 2019 Aug 20;12:6757-6767. doi: 10.2147/OTT.S216146. eCollection 2019.

8.

Peritoneal and upper genital tract tuberculosis.

Wagner A, Arsenić R, David M, Sehouli J, Vidosavljević D, Rohr I.

Med Glas (Zenica). 2020 Feb 1;17(1). doi: 10.17392/1023-20. [Epub ahead of print]

9.

Transfusion of red blood cells does not impact progression-free and overall survival after surgery for ovarian cancer.

Hunsicker O, Gericke S, Graw JA, Krannich A, Boemke W, Meyer O, Braicu I, Spies C, Sehouli J, Pruß A, Feldheiser A.

Transfusion. 2019 Dec;59(12):3589-3600. doi: 10.1111/trf.15552. Epub 2019 Oct 21.

PMID:
31633819
10.

Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review.

Schneider S, Armbrust R, Spies C, du Bois A, Sehouli J.

Arch Gynecol Obstet. 2019 Nov 25. doi: 10.1007/s00404-019-05321-7. [Epub ahead of print] Review.

PMID:
31616986
11.

miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.

Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A.

Carcinogenesis. 2019 Oct 5. pii: bgz163. doi: 10.1093/carcin/bgz163. [Epub ahead of print]

PMID:
31586203
12.

Incidence and Pattern of Spread of Lymph Node Metastasis in Patients With Low-grade Serous Ovarian Cancer.

Wafa M, Braicu EI, Muallem MZ, Richter R, Taube E, Sehouli J, Grabowski JP.

Anticancer Res. 2019 Oct;39(10):5617-5621. doi: 10.21873/anticanres.13757.

PMID:
31570458
13.

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N.

Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019.

14.

Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.

Guo F, Yang Z, Kulbe H, Albers AE, Sehouli J, Kaufmann AM.

Biomed Pharmacother. 2019 Oct;118:109371. doi: 10.1016/j.biopha.2019.109371. Epub 2019 Aug 30.

15.

Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.

Heitz F, Kommoss S, Tourani R, Grandelis A, Uppendahl L, Aliferis C, Burges A, Wang C, Canzler U, Wang J, Belau A, Prader S, Hanker L, Ma S, Ataseven B, Hilpert F, Schneider S, Sehouli J, Kimmig R, Kurzeder C, Schmalfeldt B, Braicu EI, Harter P, Dowdy SC, Winterhoff BJ, Pfisterer J, du Bois A.

Clin Cancer Res. 2020 Jan 1;26(1):213-219. doi: 10.1158/1078-0432.CCR-19-1741. Epub 2019 Sep 16.

PMID:
31527166
16.

Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey.

Urkmez E, Andac-Jones E, Cibula D, Querleu D, Halaska MJ, Driak D, Sehouli J, Grabowski JP, Inci G, Zalewski K, Minig L, Zorrero C, Sancı M, Alan M, Ledermann JA, Fotopoulou C, Gultekin M.

Int J Gynecol Cancer. 2019 Nov;29(9):1425-1430. doi: 10.1136/ijgc-2019-000567. Epub 2019 Aug 30. No abstract available.

PMID:
31473662
17.

Possible Role of the Posterior Compartment Peritonectomy, as a Part of the Complex Surgery, Regarding Recurrence Rate, Improvement of Symptoms and Fertility Rate in Patients with Endometriosis, Long-Term Follow-Up.

Abesadze E, Sehouli J, Mechsner S, Chiantera V.

J Minim Invasive Gynecol. 2019 Aug 23. pii: S1553-4650(19)30382-6. doi: 10.1016/j.jmig.2019.08.019. [Epub ahead of print]

PMID:
31449906
18.

Impact of brief prewarming on anesthesia-related core-temperature drop, hemodynamics, microperfusion and postoperative ventilation in cytoreductive surgery of ovarian cancer: a randomized trial.

Kaufner L, Niggemann P, Baum T, Casu S, Sehouli J, Bietenbeck A, Boschmann M, Spies CD, Henkelmann A, von Heymann C.

BMC Anesthesiol. 2019 Aug 22;19(1):161. doi: 10.1186/s12871-019-0828-1.

19.

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).

Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Greggi S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, Chi DS, Mahner S.

Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331. doi: 10.1136/ijgc-2019-000682. Epub 2019 Aug 15.

PMID:
31420412
20.

OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.

Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M.

Gynecol Oncol. 2019 Oct;155(1):126-134. doi: 10.1016/j.ygyno.2019.08.009. Epub 2019 Aug 13.

PMID:
31416612
21.

Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report.

Passler M, Taube ET, Sehouli J, Pietzner K.

World J Clin Oncol. 2019 Jul 24;10(7):247-255. doi: 10.5306/wjco.v10.i7.247.

22.
23.

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer.

Kulbe H, Otto R, Darb-Esfahani S, Lammert H, Abobaker S, Welsch G, Chekerov R, Schäfer R, Dragun D, Hummel M, Leser U, Sehouli J, Braicu EI.

Cells. 2019 Jul 12;8(7). pii: E713. doi: 10.3390/cells8070713.

24.

Nerve-sparing radical hysterectomy: steps to standardize surgical technique.

Muallem MZ, Diab Y, Sehouli J, Fujii S.

Int J Gynecol Cancer. 2019 Sep;29(7):1203-1208. doi: 10.1136/ijgc-2019-000410. Epub 2019 Jul 19.

PMID:
31326949
25.

Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study.

Woelber L, Eulenburg C, Kosse J, Neuser P, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fürst S, Strauss HG, Mahner S, Prieske K; AGO-CaRE 1 investigators.

Gynecol Oncol. 2019 Sep;154(3):571-576. doi: 10.1016/j.ygyno.2019.07.009. Epub 2019 Jul 17.

PMID:
31324454
26.

Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.

Canaz E, Grabowski JP, Richter R, Braicu EI, Chekerov R, Sehouli J.

Gynecol Oncol. 2019 Sep;154(3):539-546. doi: 10.1016/j.ygyno.2019.06.014. Epub 2019 Jun 21.

PMID:
31230821
27.

Anxiety of myoma patients: results of standardized interviews with the State Trait Anxiety Inventory and the Kessler 10 questionnaire.

Knudsen NI, Richter R, Kentenich H, Sehouli J, David M.

J Psychosom Obstet Gynaecol. 2019 Jun 10:1-9. doi: 10.1080/0167482X.2019.1624951. [Epub ahead of print]

PMID:
31179813
28.

Lymphadenectomy in Advanced Ovarian Neoplasms. Reply.

Harter P, Sehouli J, du Bois A.

N Engl J Med. 2019 Jun 6;380(23):2274-2275. doi: 10.1056/NEJMc1904411. No abstract available.

PMID:
31167063
29.

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer.

Dědová T, Braicu EI, Sehouli J, Blanchard V.

Front Oncol. 2019 Apr 11;9:261. doi: 10.3389/fonc.2019.00261. eCollection 2019.

30.

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer.

Meshcheryakova A, Svoboda M, Jaritz M, Mungenast F, Salzmann M, Pils D, Cacsire Castillo-Tong D, Hager G, Wolf A, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Birner P, Zimmermann P, Brindley DN, Heinze G, Zeillinger R, Mechtcheriakova D.

Comput Struct Biotechnol J. 2019 Apr 10;17:537-560. doi: 10.1016/j.csbj.2019.04.004. eCollection 2019.

31.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA.

Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.

PMID:
31046082
32.

A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer.

Vercellino GF, Erdemoglu E, Lichtenberg P, Muallem MZ, Richter R, Abu-Rustum NR, Plante M, Lécuru F, Greggi S, Monk BJ, Sagae S, Denkert C, Keller M, Alhakeem M, Hellriegel M, Dückelmann AM, Chiantera V, Sehouli J.

Arch Gynecol Obstet. 2019 Jul;300(1):191-199. doi: 10.1007/s00404-019-05164-2. Epub 2019 Apr 21.

PMID:
31006839
33.

Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213.

Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP, Sehouli J.

Support Care Cancer. 2020 Jan;28(1):73-78. doi: 10.1007/s00520-019-04778-1. Epub 2019 Apr 13.

PMID:
30980260
34.

Current practice and physicians' opinion about preoperative hair removal as a part of ERAS pathway implementation in gynecology and gynecology-oncology: a NOGGO-AGO survey of 148 gynecological departments in Germany.

Plett H, Ricciardi E, Bommert M, Veldink H, Traut A, Pietzner K, Zelal Muallem M, Sehouli J.

Arch Gynecol Obstet. 2019 Jun;299(6):1607-1618. doi: 10.1007/s00404-019-05132-w. Epub 2019 Apr 5.

PMID:
30953189
35.

Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation.

Kessler M, Hoffmann K, Fritsche K, Brinkmann V, Mollenkopf HJ, Thieck O, Teixeira da Costa AR, Braicu EI, Sehouli J, Mangler M, Berger H, Meyer TF.

Nat Commun. 2019 Mar 18;10(1):1194. doi: 10.1038/s41467-019-09144-7.

36.

Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.

Yang Z, Guo F, Albers AE, Sehouli J, Kaufmann AM.

Biomed Pharmacother. 2019 May;113:108727. doi: 10.1016/j.biopha.2019.108727. Epub 2019 Mar 12.

37.

Patients' perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life-a study of the North-Eastern-German Society of Gynecological Oncology.

Armbrust R, Neeb C, Thuss-Patience P, Lüftner D, Pietzner K, Riess H, Oskay-Öczelik G, Richter R, Keller M, Sehouli J.

Arch Gynecol Obstet. 2019 May;299(5):1385-1389. doi: 10.1007/s00404-019-05071-6. Epub 2019 Mar 5.

PMID:
30834969
38.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A.

N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.

PMID:
30811909
39.

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.

Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27.

PMID:
30810838
40.

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S.

Gynecol Oncol. 2019 May;153(2):286-291. doi: 10.1016/j.ygyno.2019.02.007. Epub 2019 Feb 11.

PMID:
30760408
41.

A report on the Marrakech International Women's Cancer Days: dialogs and implications.

Nasser S, Berek J, Ullrich A, Giordano L, Sehouli J.

Int J Gynecol Cancer. 2019 Feb;29(2):417-421. doi: 10.1136/ijgc-2018-000059. Epub 2018 Dec 21. Review.

PMID:
30718317
42.

Key regulator of cellular metabolism, estrogen-related receptor α, a new therapeutic target in endocrine-related gynecological tumor.

Liu G, Sun P, Dong B, Sehouli J.

Cancer Manag Res. 2018 Dec 12;10:6887-6895. doi: 10.2147/CMAR.S182466. eCollection 2018. Review.

43.

Arrangement of myofibroblastic and smooth muscle-like cells in superficial peritoneal endometriosis and a possible role of transforming growth factor beta 1 (TGFβ1) in myofibroblastic metaplasia.

Ibrahim MG, Sillem M, Plendl J, Taube ET, Schüring A, Götte M, Chiantera V, Sehouli J, Mechsner S.

Arch Gynecol Obstet. 2019 Feb;299(2):489-499. doi: 10.1007/s00404-018-4995-y. Epub 2018 Dec 7.

PMID:
30523440
44.

GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis.

Cabral-Marques O, Marques A, Giil LM, De Vito R, Rademacher J, Günther J, Lange T, Humrich JY, Klapa S, Schinke S, Schimke LF, Marschner G, Pitann S, Adler S, Dechend R, Müller DN, Braicu I, Sehouli J, Schulze-Forster K, Trippel T, Scheibenbogen C, Staff A, Mertens PR, Löbel M, Mastroianni J, Plattfaut C, Gieseler F, Dragun D, Engelhardt BE, Fernandez-Cabezudo MJ, Ochs HD, Al-Ramadi BK, Lamprecht P, Mueller A, Heidecke H, Riemekasten G.

Nat Commun. 2018 Dec 6;9(1):5224. doi: 10.1038/s41467-018-07598-9.

45.

Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer.

Grabowski JP, Sehouli J, Glajzer J, Worm M, Zuberbier T, Maurer M, Fluhr JW.

N Engl J Med. 2018 Nov 29;379(22):2176-2177. doi: 10.1056/NEJMc1810168. No abstract available. Erratum in: N Engl J Med. 2019 Apr 4;380(14):1386.

PMID:
30485775
46.

MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.

Klein O, Kanter F, Kulbe H, Jank P, Denkert C, Nebrich G, Schmitt WD, Wu Z, Kunze CA, Sehouli J, Darb-Esfahani S, Braicu I, Lellmann J, Thiele H, Taube ET.

Proteomics Clin Appl. 2019 Jan;13(1):e1700181. doi: 10.1002/prca.201700181. Epub 2018 Dec 14.

PMID:
30471200
47.

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A.

Gynecol Oncol. 2019 Feb;152(2):235-242. doi: 10.1016/j.ygyno.2018.11.008. Epub 2018 Nov 20.

PMID:
30466805
48.

Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.

Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H.

Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11.

PMID:
30428389
49.

Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma.

Bücker R, Schaefer C, Gruber AD, Hoppe J, Lazzerini L, Barinoff J, Sehouli J, Cichon G.

Pharm Res. 2018 Nov 8;36(1):7. doi: 10.1007/s11095-018-2533-z.

PMID:
30411161
50.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. No abstract available.

PMID:
30374648

Supplemental Content

Loading ...
Support Center